Merus NV (FRA:2GH)
€ 48.4 -0.4 (-0.82%) Market Cap: 3.34 Bil Enterprise Value: 3.04 Bil PE Ratio: 0 PB Ratio: 8.88 GF Score: 61/100

Merus NV at Stifel Healthcare Conference Transcript

Nov 16, 2022 / 06:50PM GMT
Release Date Price: €17.4 (-3.87%)
Brad Canino
Stifel Financial Corp. - Analyst

Great. Thanks, everyone, again for joining the Stifel Healthcare Conference. My name is Brad Canino, senior biotech analyst here. Really happy to have Merus share the stage with us today for a fireside chat. And we've got the CEO, Bill Lundberg here to do that with us. Maybe just take a minute, introduce the company, and then we'll dive right into Q&A as always.

Bill Lundberg
Merus NV - CEO, President & Principal Financial Officer

Sure thing. So Merus is a company that develops antibody-based therapies for oncology. These are bispecific and trispecific or multispecific antibodies based on the common light chain format. There are a variety of different multispecific antibody formats. What's really cool about our technology is that we make essentially monoclonal antibodies, but they bind to two different things. They come out of a single cell. And with that, we can stand on decades of optimizing therapies based on monoclonal antibodies.

We can do true large-scale screening. We can do all of the Fc

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot